World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
53
Citations
17793
World Ranking
3931
National Ranking
153

Overview

V H J van der Velden is affiliated with Erasmus University Rotterdam in the Netherlands and has a research focus primarily centered in the fields of medicine and biochemistry, genetics, and molecular biology. Their published work extensively covers hematology and oncology topics, among others.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these, the notable subfields of interest are:

  • Hematology
  • Public Health, Environmental and Occupational Health
  • Molecular Biology
  • Genetics
  • Oncology

Their primary research topics reflect a concentration on various blood cancers and related treatments:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research

Van der Velden has contributed to numerous publications, appearing repeatedly in a range of specialized journals. The frequent publication venues include:

  • Blood
  • Leukemia
  • Cytometry Part B Clinical Cytometry
  • HemaSphere
  • Cancers

The scientist's recent papers cover significant topics in hematology and oncology. Some key papers include:

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • The KMT2A recombinome of acute leukemias in 2023, 2023, Leukemia
  • A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study), 2020, Blood
  • Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial, 2022, Leukemia
  • 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo, 2020, Journal for ImmunoTherapy of Cancer

The scientist has frequently collaborated with several researchers in their field. Notable co-authors include:

  • Pieter Sonneveld
  • Jacques J. M. van Dongen
  • Edwin Sonneveld
  • Monika Brüggemann
  • Alberto Órfão

Best Publications

  • Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    J Gabert;E Beillard;V H J van der Velden;W Bi

  • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program

    E Beillard;N Pallisgaard;V H J van der Velden;W Bi

  • EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

    J J M van Dongen;L Lhermitte;S Böttcher;J Almeida

  • EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

    T Kalina;J Flores-Montero;V H J van der Velden;M Martin-Ayuso

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    V H J van der Velden;G Cazzaniga;A Schrauder;J Hancock

  • Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

    V H J van der Velden;A Hochhaus;G Cazzaniga;T Szczepanski

  • The MLL recombinome of acute leukemias in 2017

    C Meyer;T Burmeister;D Gröger;G Tsaur

  • Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  • The MLL recombinome of acute leukemias in 2013

    C. Meyer;J. Hofmann;T. Burmeister;D. Gröger

  • Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.

    T Flohr;T Flohr;A Schrauder;G Cazzaniga;R Panzer-Grümayer

  • Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

    Vincent H. J. van der Velden;Jeroen G. te Marvelde;Patricia G. Hoogeveen;Irwin D. Bernstein

  • Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts

    E.G. van Lochem;V.H.J. van der Velden;H.K. Wind;J.G. te Marvelde

  • IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

    R.P. Kuiper;E. Waanders;V.H. van der Velden;S.V. van Reijmersdal

  • Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.

    D Schotte;J C K Chau;G Sylvester;G Liu

  • Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10.

    V. H. J. Van Der Velden;M. P. Laan;M. R. M. Baert;R. De Waal Malefyt

  • Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

    V H J van der Velden;E R Panzer-Grümayer;G Cazzaniga;T Flohr

  • Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

    V H J Van der Velden;L Corral;M G Valsecchi;M W J C Jansen

  • Glucocorticoids: mechanisms of action and anti‐inflammatory potential in asthma

    Unknown

  • Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

    I Jedema;R M Y Barge;V H J van der Velden;B A Nijmeijer

  • Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.

    V H J van der Velden;M J Willemse;C E van der Schoot;K Hählen

  • Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia.

    V.H. van der Velden;S.A. Joosten;M.P. Willemse;E.R. van Wering

Frequent Co-Authors

Rob Pieters
Rob Pieters Princess Máxima Center
Giovanni Cazzaniga
Giovanni Cazzaniga University of Milano-Bicocca
Martin Schrappe
Martin Schrappe Kiel University
Hélène Cavé
Hélène Cavé Université Paris Cité
Andrea Biondi
Andrea Biondi University of Milano-Bicocca
Michael Dworzak
Michael Dworzak Medical University of Vienna
Jan Trka
Jan Trka Charles University
Thomas Lion
Thomas Lion Medical University of Vienna
Alberto Orfao
Alberto Orfao University of Salamanca
Rolf Marschalek
Rolf Marschalek Goethe University Frankfurt

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens up diverse opportunities in healthcare and research fields, many of which can be pursued through flexible online degree programs. For students aiming to enter nursing from a non-nursing background, 12-month accelerated nursing programs online for non nurses offer a fast track to gaining essential clinical skills and licensure.

When selecting a program, ease of admission can be a significant factor. The easiest absn programs to get into provide more accessible entry points without compromising on quality education. Similarly, those interested in becoming licensed practical nurses should consider accredited lpn programs easy to get into, ensuring a smoother application process and quicker entry into the workforce.

Advanced nursing roles, such as nurse practitioners, are critical in immunology-related patient care and research settings. Identifying the easiest np program can help prospective students efficiently plan their educational journey while preparing for specialized career pathways.

Exploring these related online degrees expands career options beyond traditional immunology roles, supporting a broader impact on healthcare through interdisciplinary expertise.

12-month accelerated nursing programs online for non nurses
easiest absn programs to get into
accredited lpn programs easy to get into
easiest np program

Best Scientists Citing V H J van der Velden

Trending Scientists

Recently Published Articles